vs
Cardio Diagnostics Holdings, Inc.（CDIO）与Moleculin Biotech, Inc.（MBRX）财务数据对比。点击上方公司名可切换其他公司
Cardio Diagnostics Holdings, Inc.是一家专注于精准心血管医疗的企业，开发并商业化整合遗传与表观遗传技术的诊断检测产品，可早期识别冠心病、心力衰竭等心血管疾病，主要服务美国市场的医疗机构、临床实验室与患者。
Moleculin Biotech, Inc.是一家临床阶段生物技术企业，专注于开发针对难治性癌症的创新肿瘤疗法，研发管线覆盖脑肿瘤、胰腺癌等罕见恶性肿瘤候选药物，主要在美国市场运营，致力于满足未被满足的临床医疗需求。
CDIO vs MBRX — 直观对比
营收规模更大
CDIO
是对方的Infinity倍
$0
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.6K | $0 |
| 净利润 | — | $15.6M |
| 毛利率 | — | — |
| 营业利润率 | — | — |
| 净利率 | — | — |
| 营收同比 | -21.2% | — |
| 净利润同比 | 3.6% | 336.2% |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDIOMBRX
| Q4 25 | $3.6K | $0 | ||
| Q3 25 | $2.9K | $0 | ||
| Q2 25 | $7.5K | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | $4.5K | $0 | ||
| Q3 24 | $6.6K | $0 | ||
| Q2 24 | $7.9K | $0 | ||
| Q1 24 | $15.9K | $0 |
净利润CDIOMBRX
| Q4 25 | — | $15.6M | ||
| Q3 25 | $-1.7M | $-25.4M | ||
| Q2 25 | $-1.7M | $-17.8M | ||
| Q1 25 | — | $-5.9M | ||
| Q4 24 | — | $-6.6M | ||
| Q3 24 | $-1.4M | $-7.0M | ||
| Q2 24 | $-1.3M | $-6.0M | ||
| Q1 24 | $-4.2M | $-6.4M |
营业利润率CDIOMBRX
| Q4 25 | — | — | ||
| Q3 25 | -59950.9% | — | ||
| Q2 25 | -22457.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -21412.9% | — | ||
| Q2 24 | -16295.6% | — | ||
| Q1 24 | -26105.3% | — |
净利率CDIOMBRX
| Q4 25 | — | — | ||
| Q3 25 | -60053.8% | — | ||
| Q2 25 | -22517.7% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -21467.6% | — | ||
| Q2 24 | -16365.9% | — | ||
| Q1 24 | -26140.0% | — |
每股收益（稀释后）CDIOMBRX
| Q4 25 | — | — | ||
| Q3 25 | $-0.98 | — | ||
| Q2 25 | $-0.97 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.73 | — | ||
| Q2 24 | $-1.71 | — | ||
| Q1 24 | $-5.93 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $8.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.0M | $15.0M |
| 总资产 | $7.8M | $22.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDIOMBRX
| Q4 25 | — | $8.9M | ||
| Q3 25 | — | $6.7M | ||
| Q2 25 | — | $7.6M | ||
| Q1 25 | — | $7.7M | ||
| Q4 24 | — | $4.3M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | — | $10.8M | ||
| Q1 24 | — | $16.8M |
股东权益CDIOMBRX
| Q4 25 | $7.0M | $15.0M | ||
| Q3 25 | $8.2M | $-26.9M | ||
| Q2 25 | $9.7M | $-3.6M | ||
| Q1 25 | — | $13.8M | ||
| Q4 24 | $9.6M | $11.2M | ||
| Q3 24 | $3.7M | $17.4M | ||
| Q2 24 | $3.1M | $19.4M | ||
| Q1 24 | $3.0M | $25.0M |
总资产CDIOMBRX
| Q4 25 | $7.8M | $22.1M | ||
| Q3 25 | $8.8M | $20.4M | ||
| Q2 25 | $10.4M | $21.6M | ||
| Q1 25 | — | $21.0M | ||
| Q4 24 | $10.6M | $16.9M | ||
| Q3 24 | $4.5M | $23.4M | ||
| Q2 24 | $4.0M | $25.6M | ||
| Q1 24 | $4.3M | $30.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.7M | $-5.4M |
| 自由现金流经营现金流 - 资本支出 | $-5.9M | — |
| 自由现金流率自由现金流/营收 | -166361.5% | — |
| 资本支出强度资本支出/营收 | 5269.1% | — |
| 现金转化率经营现金流/净利润 | — | -0.35× |
| 过去12个月自由现金流最近4个季度 | $-14.3M | — |
8季度趋势，按日历期对齐
经营现金流CDIOMBRX
| Q4 25 | $-5.7M | $-5.4M | ||
| Q3 25 | $-1.4M | $-7.2M | ||
| Q2 25 | $-1.6M | $-5.6M | ||
| Q1 25 | — | $-4.6M | ||
| Q4 24 | $-5.0M | $-5.1M | ||
| Q3 24 | $-1.2M | $-6.1M | ||
| Q2 24 | $-1.2M | $-5.9M | ||
| Q1 24 | $-1.2M | $-6.7M |
自由现金流CDIOMBRX
| Q4 25 | $-5.9M | — | ||
| Q3 25 | $-1.6M | — | ||
| Q2 25 | $-1.6M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-5.2M | — | ||
| Q3 24 | $-1.2M | — | ||
| Q2 24 | $-1.4M | $-6.0M | ||
| Q1 24 | $-1.3M | — |
自由现金流率CDIOMBRX
| Q4 25 | -166361.5% | — | ||
| Q3 25 | -54509.7% | — | ||
| Q2 25 | -21273.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -115422.6% | — | ||
| Q3 24 | -17942.3% | — | ||
| Q2 24 | -17513.3% | — | ||
| Q1 24 | -7866.9% | — |
资本支出强度CDIOMBRX
| Q4 25 | 5269.1% | — | ||
| Q3 25 | 5703.5% | — | ||
| Q2 25 | 250.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 4759.9% | — | ||
| Q3 24 | 353.3% | — | ||
| Q2 24 | 2133.4% | — | ||
| Q1 24 | 125.5% | — |
现金转化率CDIOMBRX
| Q4 25 | — | -0.35× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
